Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$15.70 USD
+0.23 (1.49%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $15.65 -0.05 (-0.32%) 5:22 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRDA 15.70 +0.23(1.49%)
Will TRDA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
New Strong Sell Stocks for March 18th
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
Other News for TRDA
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Two new option listings on May 30th
Insider Sale: Chief Scientific Officer of Entrada Therapeutics Inc (TRDA) Sells Shares
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ